Klatte Tobias, Wunderlich Heiko, Patard Jean-Jacques, Kleid Mark D, Lam John S, Junker Kerstin, Schubert Jörg, Böhm Malte, Allhoff Ernst P, Kabbinavar Fairooz F, Crepel Maxime, Cindolo Luca, De La Taille Alexandre, Tostain Jacques, Mejean Arnaud, Soulie Michel, Bellec Laurent, Bernhard Jean Christophe, Ferriere Jean-Marie, Pfister Christian, Albouy Baptiste, Colombel Marc, Zisman Amnon, Belldegrun Arie S, Pantuck Allan J
Department of Urology, David Geffen School of Medicine at UCLA, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA.
BJU Int. 2007 Jul;100(1):21-5. doi: 10.1111/j.1464-410X.2007.06877.x. Epub 2007 Apr 13.
To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited.
We retrospectively studied 10 337 patients from 12 urological centres to identify patients with N0M0 synchronous bilateral RCC; the clinicopathological features and cancer-specific survival were compared to a cohort treated for N0M0 unilateral RCC.
In all, 153 patients had synchronous bilateral solid renal tumours, of whom 135 (88%) had synchronous bilateral RCC, 118 with nonmetastatic disease; 91% had nonfamilial bilateral RCC. Bilateral clear cell RCC was the major histological subtype (76%), and papillary RCC was the next most frequent (19%). Multifocality was found in 54% of bilateral RCCs. Compared with unilateral RCC, patients did not differ in Eastern Cooperative Oncology Group performance status (ECOG PS) and T classification, but bilateral RCCs were more frequently multifocal (54% vs 16%, P < 0.001) and of the papillary subtype (19% vs 12%), and less frequently clear cell RCC (76% vs 83%, P = 0.005). For the outcome, patients with nonmetastatic synchronous bilateral RCC and unilateral RCC had a similar prognosis (P = 0.63); multifocality did not affect survival (P = 0.60). Multivariate analysis identified ECOG PS, T classification, and Fuhrman grade, but not laterality, as independent prognostic factors for cancer-specific survival.
Patients with N0M0 synchronous bilateral RCC and N0M0 unilateral RCC have a similar prognosis. The frequency of a familial history for RCC (von Hippel-Lindau disease or familial RCC) was significantly greater in bilateral synchronous than in unilateral RCC. The significant pathological findings in synchronous bilateral RCC are papillary subtype and multifocality.
鉴于非转移性(N0M0)同步双侧肾细胞癌(RCC)较为罕见,单中心经验有限,故呈现多中心经验及迄今为止最大规模的该类病例队列。
我们回顾性研究了来自12个泌尿外科中心的10337例患者,以确定N0M0同步双侧RCC患者;将其临床病理特征及癌症特异性生存率与接受N0M0单侧RCC治疗的队列进行比较。
共有153例患者患有同步双侧实性肾肿瘤,其中135例(88%)为同步双侧RCC,118例为非转移性疾病;91%为非家族性双侧RCC。双侧透明细胞RCC是主要的组织学亚型(76%),其次是乳头状RCC(19%)。54%的双侧RCC存在多灶性。与单侧RCC相比,患者在东部肿瘤协作组体能状态(ECOG PS)和T分期方面无差异,但双侧RCC多灶性更常见(54%对16%,P<0.001),乳头状亚型更多见(19%对12%),透明细胞RCC较少见(76%对83%,P = 0.005)。就预后而言,非转移性同步双侧RCC和单侧RCC患者的预后相似(P = 0.63);多灶性不影响生存率(P = 0.60)。多变量分析确定ECOG PS、T分期和Fuhrman分级为癌症特异性生存的独立预后因素,而非双侧性。
N0M0同步双侧RCC和N0M0单侧RCC患者的预后相似。双侧同步RCC中RCC(冯·希佩尔-林道病或家族性RCC)家族史的频率显著高于单侧RCC。同步双侧RCC的显著病理表现为乳头状亚型和多灶性。